Valeritas (NSDQ:VLRX) today priced an underwritten public offering of 75 million shares at 48¢ per share and accompanying warrants. The Bridgewater, N.J.-based company expects to reel in roughly $36 million in proceeds from the offering. Get the full story at our sister site, Drug Delivery Business News.
Xeris Pharmaceuticals touts data for glucagon auto-injector
Xeris Pharmaceuticals (NSDQ:XERS) touted data this month for its ready-to-use glucagon auto-injector, highlighting the device’s efficacy and usability. The Chicago-based company’s rescue pen is under review for approval by the FDA as a treatment for severe hypoglycemia in people with diabetes. Get the full story at our sister site, Drug Delivery Business News.
Valeritas inks Middle East distro deal for V-Go insulin delivery device
Valeritas (NSDQ:VLRX) said today that it signed an exclusive distribution deal with Julphar for the commercialization of its V-Go wearable insulin delivery device in the member states of the Gulf Cooperation Council. Valeritas has deals in place to bring its V-Go device to 14 countries and territories, including Australia, Slovenia and Puerto Rico. The company is […]
Nemaura develops predictive algorithms for continuous glucose monitor
Nemaura Medical (NSDQ:NMRD) said today that it successfully developed predictive algorithms to support alarm functions in its sugarBeat continuous glucose monitoring system. The England-based company touted that its device’s alarm functionality can predict a user’s glucose level five minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with 90% accuracy. […]
Senseonics reports mixed Q3 results
Shares in Senseonics (NYSE:SENS) fell today after the medical device maker missed EPS expectations but met sales estimates on Wall Street with its third quarter financial results. The Germantown, Md.-based company posted a net loss of -$31.9 million on sales of $5.2 million for the 3 months ended Sept. 30. Quarterly net losses were up 83% on sales […]
Valeritas posts Street-beating Q3, sales up 37%
Shares in Valeritas (NSDQ:VLRX) rose today after the medical device maker topped expectations on Wall Street with its third-quarter financial results. The Bridgewater, N.J.-based company posted a net loss of -$11.5 million on sales of $6.9 million for the 3 months ended Sept. 30. Sales were up 37% compared with the same period last year. Get the […]
Insulet inks deal with Samsung to develop smartphone-controlled Omnipod
Insulet (NSDQ:PODD) said this week that it inked a deal with Samsung to develop an Omnipod insulin delivery system that would allow users to control their insulin pump therapy with a Galaxy smartphone. If approved, the system would be the first of its kind, according to the Billerica, Mass.-based company. Get the full story at our […]
Senseonics wins another FDA approval for its implantable CGM
Senseonics (NYSE:SENS) said this week that it won another FDA approval for its implantable continuous glucose monitoring system, giving nurse practitioners and physicians assistants the ability to implant and remove the Eversense device. When the product was first approved by the FDA in June, only trained physicians were allowed to conduct the sensor insertion and removal procedures. Get […]
Dexcom raises outlook after Q3 results top Wall Street estimates
Dexcom (NSDQ:DXCM) raised its full-year outlook yesterday after the medical device maker topped expectations on Wall Street with its third-quarter financial results. The San Diego, Calif.-based company posted profits of $46.6 million, or 53¢ per share, on sales of $266.7 million for the 3 months ended Sept. 30, for sales growth of 44% compared with the […]
Medtronic touts five-year data for In.Pact Admiral drug-coated balloon
Medtronic (NYSE:MDT) today touted five-year data for its In.Pact Admiral drug-coated balloon, highlighting the durability and efficacy of its device in people with peripheral artery disease in the superficial femoral and popliteal arteries. The company presented five-year results from its pivotal In.Pact SFA trial at the 2018 Vascular Interventional Advances conference. Get the full story at […]
New diabetes software from Klue features mealtime insulin reminders
Digital health company Klue announced this week that its latest AI-driven software is a module designed for people with Type I diabetes. The technology features autonomous meal detection capabilities and provides mealtime medication reminders to users, according to the San Francisco, Calif.-based company. Get the full story at our sister site, Drug Delivery Business News.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 74
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube